Homology Medicines, Inc. announced the promotion of Albert Seymour, Ph.D., to member of the Board of Directors. He is succeeding Arthur Tzianabos, Ph.D., who has been appointed as Chairperson of Homology's Board of Directors. Dr. Tzianabos and Dr. Seymour joined Homology in 2016 as CEO & President and Chief Scientific Officer, respectively, and they helped to build the Company into a clinical-stage organization with programs spanning nuclease-free gene editing, gene therapy and gene therapy-delivered monoclonal antibodies (GTx-mAb).

Dr. Seymour has driven the translation of Homology's proprietary in vivo gene therapy and nuclease-free gene editing platform from early research and discovery to clinical development programs for rare diseases. Prior to Homology, he was the Senior Vice President and Head of Global Research and Nonclinical Development at Shire plc. Before Shire, he spent 14 years at Pfizer Inc., leading teams in the application of human genetics and computational biology to discover and develop therapeutics and pharmacogenomics strategies in diabetes, inflammatory diseases and oncology.Dr. Tzianabos will remain on the Board of Oxford Biomedica Solutions, a Manufacturing and Innovation Business that Homology established with Oxford Biomedica.

In conjunction with Homology's leadership transition, Kush Parmar, M.D., Ph.D., has stepped down as Chair and member of the Board of Homology.